Clinical Trials Directory

Trials / Unknown

UnknownNCT03432780

Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer

Randomized Phase II Clinical Study of Radiation Therapy, Hormone Therapy and Chemotherapy With Docetaxel Versus Radiation Therapy and Hormone Therapy in Patients With High-Risk Localized Prostate Cancer (Stage III and IV)"

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
134 (actual)
Sponsor
Spanish Oncology Genito-Urinary Group · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

A prospective, multicenter, parallel-group, open-label, randomized, phase II Clinical Study of Radiation Therapy, Hormone Therapy and Docetaxel Versus Radiation Therapy and Hormone Therapy in Patients with High-Risk Localized Prostate Cancer (Stage III and IV) whose primary objective is determine the percentage of patients free of biochemical recurrence within 5 years of receiving a combination of radiation therapy with docetaxel associated with hormone therapy or the standard of care of radiation therapy and hormone therapy in patients with stage III and IV localized prostate cancer with a poor prognosis.

Detailed description

Randomized Phase II Clinical Study of Radiation Therapy, Hormone Therapy and Chemotherapy with Docetaxel Versus Radiation Therapy and Hormone Therapy in Patients with High-Risk Localized Prostate Cancer (Stage III and IV) Primary Objective: To determine the percentage of patients free of biochemical recurrence within 5 years of receiving a combination of radiation therapy with docetaxel associated with hormone therapy or the standard of care of radiation therapy and hormone therapy in patients with stage III and IV localized prostate cancer with a poor prognosis. Design: A prospective, multicenter, multidisciplinary, parallel-group, open-label study with randomized group assignment.

Conditions

Interventions

TypeNameDescription
DRUGDocetaxel
BIOLOGICALHormone and radiation therapy
RADIATIONRadiation therapy

Timeline

Start date
2008-12-18
Primary completion
2023-11-14
Completion
2023-11-14
First posted
2018-02-14
Last updated
2021-01-22

Source: ClinicalTrials.gov record NCT03432780. Inclusion in this directory is not an endorsement.